title: Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.
abstract: YKL-40 is the most highly expressed gene in glioblastoma compared with normal brain tissues. Previous studies assessing the association between YKL-40 and survival in glioblastoma patients reported varying magnitude of estimates. The objective of this meta-analysis was to determine the prognostic value of YKL-40 in glioblastoma patients. PubMed and Embase databases were searched for studies relating to YKL-40 and prognosis of glioblastoma patients. Studies reporting estimates for overall survival by YKL-40 expression in glioblastoma patients were considered eligible. A meta-analysis of included studies was performed using fixed- or random-effect model to calculate the pooled hazard ratio (HR) and 95 % confidence interval (95%CI). Eight studies were ultimately considered eligible and included into the meta-analysis. Those eight studies included 1241 glioblastoma patients. Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001). Meta-analysis of studies with adjusted estimates and high quality showed that high YKL-40 expression was independently associated with worse overall survival in glioblastoma patients (HR = 1.50, 95%CI 1.35-1.66, P < 0.001). Both subgroup analysis and sensitivity analysis validated the obvious association between high YKL-40 expression and worse overall survival in glioblastoma patients. High YKL-40 expression is independently and markedly associated with worse overall survival in glioblastoma patients. YKL-40 is a good predictive biomarker of prognosis in glioblastoma patients.
authors.affiliation: Department of Neurosurgery, The First People's Hospital of Nanning, Nanning, 530022, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Qin
authors.affiliation: Department of Neurology, The First People's Hospital of Nanning, Nanning, 530022, China. docmedu@126.com.
authors.forename: Xianfeng
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Neurology, The First People's Hospital of Nanning, Nanning, 530022, China.
authors.forename: Zilong
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Department of Neurosurgery, The First People's Hospital of Nanning, Nanning, 530022, China.
authors.forename: Guangcha
authors.initials: G
authors.lastname: Liao
authors.affiliation: Department of Neurology, The First People's Hospital of Nanning, Nanning, 530022, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Su
authors.affiliation: Department of Neurology, The First People's Hospital of Nanning, Nanning, 530022, China.
authors.forename: Yaode
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Affiliated Hospital of Weifang Medical University, Weifang, 262200, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D001932:Brain Neoplasms / Q000378:metabolism*; D000071451:Chitinase-3-Like Protein 1 / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D011379:Prognosis; D017594:Publication Bias; D016019:Survival Analysis
chemical_list: C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1
keywords: Glioblastoma; Prognostic marker; YKL-40